Harvard Biosci Stock Price, News & Analysis

Harvard Bioscience (Nasdaq: HBIO) has launched SmartStudy™, a new feature for its Buxco® Inhalation System, enhancing precision and cost-efficiency in small animal research. This technology allows researchers to stop the delivery of test articles to individual subjects once the desired dosage is achieved, minimizing error and optimizing resource use. Demonstrations of SmartStudy™ occurred at the Society of Toxicology meeting and will continue at the American Thoracic Society conference. The innovation aims to significantly improve inhalation study methodologies.

Harvard Bioscience, Inc. (Nasdaq: HBIO) is set to announce its financial results for Q1 2022 on May 4, 2022, before market opening. A conference call to discuss these results will take place at 8:00 a.m. ET. Interested parties can join the call by calling toll-free 1 (877) 303-7611 or international 1 (970) 315-0445, using conference ID #6757353. The call will also be available via webcast on the company’s investor relations website.

Harvard Bioscience develops technologies for research and drug development, serving a wide range of clients globally.

Harvard Bioscience reported a 7% revenue increase year-over-year in Q4 2021, totaling $33.1 million, despite global supply chain challenges. Gross margin improved to 59%, fueled by a stronger product mix. Pre-clinical product revenue rose by 18% for the full year, while CMT products grew by 9% in Q4. However, operating income dipped to $1.7 million due to rising material and labor costs. The company anticipates 10-13% revenue growth for 2022, with plans for increased investment in sales and R&D.

Harvard Bioscience (Nasdaq: HBIO) is set to announce its fourth-quarter financial results for the period ending December 31, 2021, on March 8, 2022, prior to market opening. The company will hold a conference call at 8:00 a.m. Eastern Time to discuss these results. Investors can participate by dialing the provided numbers or via the live webcast accessible through their website. Harvard Bioscience specializes in developing technologies for fundamental research and drug development, serving various sectors from academia to pharmaceuticals.

Harvard Bioscience reported a 23% year-over-year revenue growth for Q3 2021, reaching $29.7 million, with pre-clinical product revenue up 28% and Cellular and Molecular Technologies (CMT) product revenue up 19%. Operating income showed a slight increase from $0.2 million to $0.5 million. Despite ongoing global supply chain disruptions impacting costs, adjusted operating margin remained solid at 13.3%. The company expects revenue growth of 15% to 17% for the year, up from previous estimates of 12% to 15%.

Harvard Bioscience (Nasdaq: HBIO) will announce its third-quarter financial results on November 3, 2021, prior to market opening. The announcement will be followed by a conference call at 8:00 a.m. Eastern Time to discuss the results. Interested parties can join the call by dialing 1 (877) 303-7611 (toll-free) or 1 (970) 315-0445 (international), using conference ID # 8391005. Additionally, a live webcast will be available on the company's website, where the earnings release and presentation will also be accessible.

Harvard Bioscience, Inc. (Nasdaq: HBIO) reported a 25% year-over-year revenue growth for Q2 2021, reaching $29.2 million, driven by strong demand in pre-clinical and Cellular and Molecular (CMT) products, which grew by 20% and 22%, respectively. Despite higher global supply chain costs affecting operating margins, adjusted operating margins remained robust at 14.6%. Looking ahead, the company anticipates a 12% to 15% revenue growth for the fiscal year. Operating income was impacted, showing a loss per share of $(0.01), with adjusted diluted EPS at $0.06.

Harvard Bioscience (Nasdaq: HBIO) will release its financial results for Q2 2021 on August 5, 2021, prior to market opening. The announcement will be followed by a conference call at 8:00 a.m. ET, accessible via toll-free number 1 (877) 303-7611 or international number 1 (970) 315-0445, with conference ID # 6293853. The call will also be webcast through the Harvard Bioscience website. The results and accompanying slide presentation will be available on the Investor Relations section of their site.

Harvard Bioscience (Nasdaq: HBIO) reported a revenue increase of 14% for Q1 2021, totaling $27 million, driven by strong pre-clinical product demand which rose 24%. This growth follows continued momentum from Q4 2020, aided by effective sales strategies and improved academic lab sales. The operating loss improved significantly, with adjusted operating income reaching $3.2 million and an adjusted operating margin of 12%. The company expects revenue growth of 10% to 14% for 2021, indicating a positive outlook for future business performance.